Literature DB >> 26585925

MALDI-TOF-MS Assay to Detect the Hemizygous 22q11.2 Deletion in DNA from Dried Blood Spots.

Lisa J Kobrynski1, Golriz K Yazdanpanah2, Deborah Koontz3, Francis K Lee3, Robert F Vogt3.   

Abstract

BACKGROUND: A hemizygous deletion of 1.5-3 Mb in 22q11.2 causes a distinct clinical syndrome with variable congenital defects. Current diagnostic methods use fluorescent in situ hybridization (FISH) or comparative genomic hybridization by microarray to detect the deletion. Neither method is suitable for newborn screening (NBS), since they cannot be performed on dried blood spots (DBS). We developed a MALDI-TOF-MS assay that uses DBS to measure the hemizygous deletion of UFD1L, located within the 22q11.2 region.
METHODS: We used DBS from 54 affected patients, previously tested by FISH or microarray, and 100 cord blood samples to evaluate the performance of the MALDI-TOF-MS assay. With a single primer pair, a 97-base oligonucleotide within UFD1L was amplified, as was a sequence on chromosome 18 that differs by 2 nucleotides. A multiplexed, single-base extension reaction created allele-specific products for MALDI-TOF-MS detection. The products were spotted onto a silicon chip, and the height of the spectral peaks identified the relative amounts of target and reference gene.
RESULTS: The median ratio of the spectral peak for each UFD1L target:reference base was 0.96 and 0.99 for controls, compared with 0.35 and 0.53 for 22q11 deletion syndrome patients. There was 100% concordance between FISH/microarray and MALDI-TOF-MS in all patients with 22q11.2 deletion syndrome.
CONCLUSIONS: This method can be reliably performed with DBS and is suitable for high sample throughput. This assay may be considered for use in population-based NBS for 22q11.2 deletion.
© 2015 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26585925      PMCID: PMC5726890          DOI: 10.1373/clinchem.2015.247148

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  27 in total

1.  Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients.

Authors:  C Carlson; H Sirotkin; R Pandita; R Goldberg; J McKie; R Wadey; S R Patanjali; S M Weissman; K Anyane-Yeboa; D Warburton; P Scambler; R Shprintzen; R Kucherlapati; B E Morrow
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

2.  Assessment of DNA contamination from dried blood spots and determination of DNA yield and function using archival newborn dried blood spots.

Authors:  Suzanne K Cordovado; Marie C Earley; Miyono Hendrix; Rena Driscoll-Dunn; Michael Glass; Patricia W Mueller; W Harry Hannon
Journal:  Clin Chim Acta       Date:  2008-12-31       Impact factor: 3.786

3.  Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  A F Jawad; D M McDonald-Mcginn; E Zackai; K E Sullivan
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

4.  Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.

Authors:  Antonia Kwan; Roshini S Abraham; Robert Currier; Amy Brower; Karen Andruszewski; Jordan K Abbott; Mei Baker; Mark Ballow; Louis E Bartoshesky; Francisco A Bonilla; Charles Brokopp; Edward Brooks; Michele Caggana; Jocelyn Celestin; Joseph A Church; Anne Marie Comeau; James A Connelly; Morton J Cowan; Charlotte Cunningham-Rundles; Trivikram Dasu; Nina Dave; Maria T De La Morena; Ulrich Duffner; Chin-To Fong; Lisa Forbes; Debra Freedenberg; Erwin W Gelfand; Jaime E Hale; I Celine Hanson; Beverly N Hay; Diana Hu; Anthony Infante; Daisy Johnson; Neena Kapoor; Denise M Kay; Donald B Kohn; Rachel Lee; Heather Lehman; Zhili Lin; Fred Lorey; Aly Abdel-Mageed; Adrienne Manning; Sean McGhee; Theodore B Moore; Stanley J Naides; Luigi D Notarangelo; Jordan S Orange; Sung-Yun Pai; Matthew Porteus; Ray Rodriguez; Neil Romberg; John Routes; Mary Ruehle; Arye Rubenstein; Carlos A Saavedra-Matiz; Ginger Scott; Patricia M Scott; Elizabeth Secord; Christine Seroogy; William T Shearer; Subhadra Siegel; Stacy K Silvers; E Richard Stiehm; Robert W Sugerman; John L Sullivan; Susan Tanksley; Millard L Tierce; James Verbsky; Beth Vogel; Rosalyn Walker; Kelly Walkovich; Jolan E Walter; Richard L Wasserman; Michael S Watson; Geoffrey A Weinberg; Leonard B Weiner; Heather Wood; Anne B Yates; Jennifer M Puck; Vincent R Bonagura
Journal:  JAMA       Date:  2014-08-20       Impact factor: 56.272

5.  Multiplexed quantitative real-time PCR to detect 22q11.2 deletion in patients with congenital heart disease.

Authors:  Aoy Tomita-Mitchell; Donna K Mahnke; Joshua M Larson; Sujana Ghanta; Ying Feng; Pippa M Simpson; Ulrich Broeckel; Kelly Duffy; James S Tweddell; William J Grossman; John M Routes; Michael E Mitchell
Journal:  Physiol Genomics       Date:  2010-06-15       Impact factor: 3.107

Review 6.  Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes.

Authors:  Lisa J Kobrynski; Kathleen E Sullivan
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

7.  Molecular diagnosis of 22q11.2 deletion and duplication by multiplex ligation dependent probe amplification.

Authors:  Andrea C Stachon; Berivan Baskin; Adam C Smith; Andrea Shugar; Cheryl Cytrynbaum; Leona Fishman; Roberto Mendoza-Londono; Regan Klatt; Ahmed Teebi; Peter N Ray; Rosanna Weksberg
Journal:  Am J Med Genet A       Date:  2007-12-15       Impact factor: 2.802

8.  Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years.

Authors:  Antonia Kwan; Joseph A Church; Morton J Cowan; Rajni Agarwal; Neena Kapoor; Donald B Kohn; David B Lewis; Sean A McGhee; Theodore B Moore; E Richard Stiehm; Matthew Porteus; Constantino P Aznar; Robert Currier; Fred Lorey; Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2013-07       Impact factor: 10.793

9.  A method for accurate detection of genomic microdeletions using real-time quantitative PCR.

Authors:  Rosanna Weksberg; Simon Hughes; Laura Moldovan; Anne S Bassett; Eva W C Chow; Jeremy A Squire
Journal:  BMC Genomics       Date:  2005-12-13       Impact factor: 3.969

10.  Unambiguous molecular detections with multiple genetic approach for the complicated chromosome 22q11 deletion syndrome.

Authors:  Chen Yang; Cheng-Hung Huang; Mei-Leng Cheong; Kun-Long Hung; Lung-Huang Lin; Yeong-Seng Yu; Chih-Cheng Chien; Huei-Chen Huang; Chan-Wei Chen; Chi-Jung Huang
Journal:  BMC Med Genet       Date:  2009-02-25       Impact factor: 2.103

View more
  2 in total

1.  Identification of 22q11.2 Deletion Syndrome via Newborn Screening for Severe Combined Immunodeficiency.

Authors:  Jessica C Barry; Terrence Blaine Crowley; Soma Jyonouchi; Jennifer Heimall; Elaine H Zackai; Kathleen E Sullivan; Donna M McDonald-McGinn
Journal:  J Clin Immunol       Date:  2017-05-24       Impact factor: 8.317

Review 2.  Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune Dysregulatory Diseases).

Authors:  Annely M Richardson; Ann M Moyer; Linda Hasadsri; Roshini S Abraham
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.